Advertisement

Thalidomide: Induction Therapy

  • Francis K. Buadi
  • S. Vincent Rajkumar
Part of the Contemporary Hematology book series (CH)

Introduction

Multiple myeloma (MM) is a clonal stem cell disorder characterized by the presence of a monoclonal protein in the serum or urine, osteolytic bone lesions, increased plasma cells in the bone marrow, anemia, renal insufficiency, and hypercalcemia.1,2 The initial treatment of patients with MM has gone through changes over the years. The current management concept is to increase remission rates, progression-free survival (PFS), overall survival, and quality of life since MM is still incurable.3,4 However, with the current availability of multiple targeted therapies with comparable and sometimes superior efficacy and improved survival, the side-effect profile and long-term toxicity has become a major factor.

High-dose therapy with autologous stem cell transplant as part of initial therapy is currently considered the standard of care for patients who are eligible for transplant.5,6It is therefore important to avoid stem cell toxic drugs as part of induction therapy in patients...

Keywords

Multiple Myeloma Deep Vein Thrombosis Eastern Cooperative Oncology Group Autologous Stem Cell Transplantation Complete Response Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860–73.PubMedCrossRefGoogle Scholar
  2. 2.
    Bataille R, Harousseau JL. Multiple myeloma (100 Refs) [Review]. N Engl J Med 1997 ;336 (23):1657–64.PubMedCrossRefGoogle Scholar
  3. 3.
    Rajkumar SV, Kyle RA. Multiple myeloma: Diagnosis and treatment. Mayo Clin Proc 2005;80: 1371–82.PubMedCrossRefGoogle Scholar
  4. 4.
    Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): Consensus statement. Mayo Clin Proc 2007;82:323–41.PubMedCrossRefGoogle Scholar
  5. 5.
    Attal M, Harousseau JL, Stoppa A M e t a l A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335 (2):91–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma [see comment] N Engl J Med 2003;349 (26):2495–502.PubMedCrossRefGoogle Scholar
  7. 7.
    Harousseau J-L, Marit G, Caillot D, et al. VELCADE/Dexamethasone (Vel/Dex) versus VA D as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): An interim analysis of the IFM 2005–01 randomized multicenter phase III trial. Blood 2006;108(11):56.CrossRefGoogle Scholar
  8. 8.
    Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [see comments]. N Engl J Med 1999;341(21):1565–71.PubMedCrossRefGoogle Scholar
  9. 9.
    Rajkumar SV, Blood E, Vesole DH, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Stirling DI. Pharmacology of thalidomide. Semin Hematol 2000;37:5–14.CrossRefGoogle Scholar
  11. 11.
    D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91(9):4082–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Olson KB, Hall TC, Horton J Khung CL, Hosley HF. Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer. Clin Pharmacol Ther 1965;6(3):292–7.PubMedGoogle Scholar
  13. 13.
    Rajkumar SV, Fonseca R, Dispenzieri A et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000;75:897–902.PubMedCrossRefGoogle Scholar
  14. 14.
    Kneller A, Raanani P, Hardan I, e t al. Therapy with thalidomide in refractory multiple myeloma‴The revival of an old drug. Br J Haematol 2000;108:391–3.PubMedCrossRefGoogle Scholar
  15. 15.
    Juliusson G Celsing F, Turesson I, Lenhoff S, Adriansson M Malm C Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000;109:89–96.PubMedCrossRefGoogle Scholar
  16. 16.
    Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy. Blood 2000 ;96: 2943–50.PubMedGoogle Scholar
  17. 17.
    Weber DM, Gavino M, Delasalle K, Rankin K, Giralt S, Alexanian R. Thalidomide alone or with dexamethasone for multiple myeloma. Blood 19909;94 (Suppl 1):604a (A 2686).Google Scholar
  18. 18.
    Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319–23.PubMedCrossRefGoogle Scholar
  19. 19.
    Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21(1):16–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Cavo M Zamagni E, Tosi P et al. First-line therapy with thalidomide and dex-amethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004;89:826–31.PubMedGoogle Scholar
  21. 21.
    Alexanian R Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990;33(2):86–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106(1):35–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Rajkumar SV. The death of VAD as initial therapy for multiple myeloma. Blood 2005;106:2–3.CrossRefGoogle Scholar
  24. 24.
    Rajkumar SV, Hussein M, Catalano J, et al. A randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as primary therapy for newly diagnosed multiple myeloma. Blood 2006;108(11):238a. Abstract 795.Google Scholar
  25. 25.
    Abdelkefi A, Torjman L, Ben Romdhane N, et al. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. Bone Marrow Transplant 2005;36(3):193–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Breitkreutz I, Lokhorst HM, Raab MS, et. al Thalidomide in newly diagnosed multiple myeloma: Influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007.Google Scholar
  27. 27.
    Myeloma Trialists' Collaborative Group. Combination chemotherapy versus mel-phalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998;16(12):3832–42.Google Scholar
  28. 28.
    Alexanian R, Dimopoulos M The treatment of multiple myeloma. (54 Refs). N Engl J Med 1994;330(7):484–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W Glick JH. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: Results of Eastern Cooperative Oncology Group Study E2479. Cancer 1997;79(8):1561–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Palumbo A Bringhen S Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006;367:825–31.PubMedCrossRefGoogle Scholar
  31. 31.
    Facon T, Mary JY, Hulin C, et al. Major superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood 2005;106(11):230a (A780).Google Scholar
  32. 32.
    Hulin C, Virion J, Leleu X et al. Comparison of melphalan-prednisone-thalido-mide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01–01 trial. J Clin Oncol (Meeting Abstracts) 2007;25(18_suppl):8001.Google Scholar
  33. 33.
    Ludwig H, Drach J, Tóthová E, et al. Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: An interim analysis. J Clin Oncol 2005;23(16S):6537.Google Scholar
  34. 34.
    Offidani M Corvatta L, Piersantelli M-N, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma 10.1182/blood-2006-03-013086. Blood 2006;108(7):2159–64.PubMedCrossRefGoogle Scholar
  35. 35.
    Harousseau JL, Attal M. The role of autologous hematopoietic stem cell transplantation in multiple myeloma [Review]. Semin Hematol 1997;34(1 Suppl 1):61–6.PubMedGoogle Scholar
  36. 36.
    Barlogie B, Jagannath S, Epstein J, et al. Biology and therapy of multiple myeloma in 1996. Semin Hematol 1997;34:67–72.PubMedGoogle Scholar
  37. 37.
    Gertz MA, Pineda AA, Chen MG, et al. Refractory and relapsing multiple myeloma treated by blood stem cell transplantation. Am J Med Sci 1995;309(3):152–61.PubMedCrossRefGoogle Scholar
  38. 38.
    Kovacsovics T, Delaly A. Intensive treatment strategies in myeloma. Semin Hematol 1997;34:49–60.PubMedGoogle Scholar
  39. 39.
    Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma [see comment]. N Engl J Med 2006;354 (10):1021–30.PubMedCrossRefGoogle Scholar
  40. 40.
    Fine HA, Figg WD, Jaeckle K, et al. A phase II trial of the anti-angiogenic agent thalido-mide in patients with recurrent high-grade gliomas. J Clin Oncol 2000;18(4):708–15.PubMedGoogle Scholar
  41. 41.
    Barlogie B Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98(2):492–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Rajkumar SV. Thalidomide therapy and deep venous thrombosis in multiple myeloma [comment]. Mayo Clin Proc 2005;80(12):1549–51.PubMedCrossRefGoogle Scholar
  43. 43.
    Rajkumar SV, Gertz MA, Witzig TE. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med 2000;343:972–3.PubMedCrossRefGoogle Scholar
  44. 44.
    Palumbo A, Falco P, Corradini P, et al. Melphalan, Prednisone and lenalidomide treatment for newly diagnosed myeloma. A report from the GIMEMA Italian Multiple Myeloma Network. J. Clin Oncol 2007;25:4459–4465PubMedCrossRefGoogle Scholar
  45. 45.
    Mateos M-V Hernandez J-M, Hernandez M-T, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study 10.1182/blood-2006-04-019778. Blood 2006;108(7):2165–72.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Francis K. Buadi
    • 1
  • S. Vincent Rajkumar
    • 1
  1. 1.Mayo Clinic College of MedicineRochesterUSA

Personalised recommendations